From The Ottawa Citizen:
“The federal Patented Medicines Price Review Board thinks companies would be happy to sell Canada their new drugs for much less than they get in many other 36 OECD countries. It doesn’t look like they’re right.”
To view article, please go to: https://ottawacitizen.com/opinion/stewart-and-bradford-stiff-price-controls-will-hurt-canadians-access-to-ground-breaking-drugs